U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449/PTO			Complete if Known				
1	INFORMATION I	DISCLO	SURE	Application Number	10/584,341	OIPE		
	STATEMENT BY	APPLI	CANT	Filing Date	12/23/2004		40	
	Data C. basitta di Annii 4E 2000			First Named Inventor	Martin Maurer	7	91	
Date Submitted: April 15, 2008				Art Unit	Unassigned	APR 1 6	2008	
(use as many shee	ts as ne	cessary)	Examiner Name	Unassigned	12	- <i>[5]</i>	
Sheet	1	of	1	Attorney Docket Number	085449-0198	The same of the sa		

			U.S. PATENT DO	CUMENTS		
	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
	No.1	Number-Kind Code ² (if known)		Cited Document	Passages or Relevant Figures Appear	
	A1	US-2001/0052137	12-13-2001	Klein		

=	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
	A2	WO 97/41854	11-13-1997	UNIV PENNSYLAVANIA ET AL		
	А3	WO 02/092635	11-21-2002	UNIV CALIFORNIA		
		<u> </u>				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ₆
	A4	FABER KENNETH A ET AL: "Dose-response characteristics of neonatal exposure to genistein on pituitary responsiveness to gonadotropin releasing hormone and volume of the sexually dimorphic nucleus of the preoptic area (SDN-POA) in postpubertal castrated female rate" Reproductive Toxicology, Bd. 7, No 1, 1993, pages 35-39, XP002455406.	
	A5	KATOH MASARU: "WNT2 and human gastrointestinal cancer (Review). "International Journal of Molecular Medicine, Bd. 12, No. 5, November 2003 pages 811-816, XP009090899.	
	A6	O'BRIEN W T ET AL: "An Investigation of the role of Glycogen Synthase Kinase (GSK-3BETA) in Lithium- Sensitive Behavior" Abstracts of the Society for Neuroscience, Society for Neuroscience, Washington, DC, US Bd. 26, No. ½, November 4, 2000, page 416, XP009007122.	
	Α7	MEIJER, LAURENT ET AL: "Pharmacological inhibitors of glycogen synthase kinase 3" Trends In Pharmacological Sciences, Bd. 25, No. 9, September 2004, pages 471-480, XP004552644.	
	A8	FUJII NAOAKI ET AL: "An antagonist of disheveled protein-protein interactioin suppresses beta-catenin-dependent tumor cell growth" Cancer Research, Bd. 67, No. 2, January 2007, pages 573-579, XP002455408.	

l ` . ` . ` .	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.